Safety and Efficacy Study of I-131 Tositumomab in Patients With Relapsed/Refractory Hodgkin's Lymphoma

PHASE1/PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

June 30, 2007

Primary Completion Date

January 31, 2014

Study Completion Date

November 30, 2015

Conditions

Hodgkin's Disease

Interventions

DRUG

I-131 Tositumomab therapeutic regimen

Tositumomab and I-131 tositumomab are given intravenously. A test dose is given followed by a larger treatment dose.

Trial Locations (1)

Johns Hopkins Medical Institutions, Baltimore